NEW YORK, March 7 /PRNewswire-FirstCall/ - Genesis Bioventures, Inc. (GBI) - (OTCBB:GBIW) and its business advisor, Experigen Management Company (Experigen) announced today that Lou Lome has joined GBI as a Scientific Advisor. Mr. Lome is noted for his scientific contributions spanning three decades of service to the United States government at the highest levels of science at the Office of Research and Development at the Central Intelligence Agency, the Innovative Science & Technology Office of the Strategic Defense Initiative Organization, the Department of Defense Science and Technology Program in Electronic Warfare, and most recently as a research scientist for the Institute for Defense Analysis (IDA). Mr. Lome's experience includes technology innovation in communications and information technology, VLSI, image and signal processing programs, advanced information surveillance, quantum computing, and nanotechnology. "We are very pleased Mr. Lome has joined GBI's advisory team," said Greg McCartney, President of GBI. "His outstanding science background, his extensive network of world leading scientists and his in-depth experience in large scale project management becomes very important to our success as we continue to build GBI and manage our current investment companies to profitability." "We are very serious about increasing GBI's commercial and scientific focus," said Douglas C. Lane of Experigen. "Mr. Lome's experience in advanced satellite surveillance systems and RFID devices will help us exploit a new and potentially exciting channel to our Prion Developmental Laboratory company's opportunities: animal tracking and record maintenance systems that are becoming an increasing mandate of the beef import and export industry by foreign and domestic governments. And, with Mr. Lome's participation, we now stand to benefit from synergies in oncology and nanotechnology that are being developed globally which complement and may increase our Biomedical Diagnostic, Inc. company's MSA breast cancer diagnostic technology, and possible therapeutic opportunities that may develop as a result." Mr. Lome is also an advisor to the International Technology Roadmap for Semiconductors (ITRS), Emerging Research Devices (ERD), NASA Jet Propulsion Laboratory, Oak Ridge National Laboratory, and the Nanotechnology Science & Technology Institute. He is a member of over twenty exclusive science professional societies, including senior member of the Institute for Electrical and Electronic Engineers (IEEE), life member of the American Physical Society (APS), fellow of the Optical Society of America (OSA), Society for Photo-optical Interpretation Engineers (SPIE), Society for Mathematical Biology (SMB), among others, and he is Chair of numerous conferences within IEEE and SPIE, and the Nanotech 2005 Government Forum. About Experigen Experigen is a management company retained by Genesis Bioventures, Inc. to develop and advance GBI's investment portfolio, financing and operations. About Genesis Bioventures, Inc. Genesis Bioventures, Inc. is a biomedical development corporation focusing on the development and marketing of novel diagnostics and therapeutics in oncology and neurodegenerative diseases. Statements in this press release that are not strictly historical facts are "forward looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements. CONTACT: GBI Investor Relations: (604) 542-0820, email@example.com, www.gnsbio.com Experigen: (310) 443-4100, firstname.lastname@example.org, www.experigen.com
SOURCE Genesis Bioventures, Inc.